Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of March 2020, with the report dated March 23, 2020. The filing discloses a material amendment to a strategic collaboration agreement with Eli Lilly and Company regarding the development of Tau Morphomer small molecules for Alzheimer's disease and other neurodegenerative conditions.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the period. The primary financial disclosure relates to a restructuring of milestone payments under the License Agreement:
- Immediate Milestone: A payment of 10 million Swiss Francs (CHF) due on or before March 31, 2020.
- Future Milestone: A payment of 60 million CHF due within 60 days after the first patient is dosed in a Phase 2 clinical trial in the United States or European Union.
- Previous Obligation: These payments replace a single 30 million CHF milestone that was originally due on or before March 31, 2020.
Material Changes Versus Prior Period
The material change is the execution of the Second Amendment to the License Agreement on March 20, 2020. This amendment alters the timing and total potential value of near-term cash inflows from Eli Lilly. The original 30 million CHF obligation was split into a smaller immediate payment (10 million CHF) and a significantly larger contingent payment (60 million CHF) tied to clinical trial progress.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on general outlook, or a discussion of risks beyond the context of the agreement amendment. The 60 million CHF milestone is contingent upon the successful dosing of the first patient in a Phase 2 clinical trial, introducing execution risk regarding the timeline of clinical development.
Investor Verification Checklist
- Verify the exact exchange rate between Swiss Francs and USD for the 10 million CHF immediate payment.
- Confirm the current status of the Phase 2 clinical trial to assess the likelihood and timing of the 60 million CHF milestone.
- Review the full text of the Second Amendment (Exhibit 10.1) for any additional terms or conditions not summarized in the filing.
- Check subsequent filings for the actual receipt of the 10 million CHF payment by the March 31, 2020 deadline.